重新连接发作的大脑:干细胞移植作为治疗中的神经调节架构师
Zijie Wang1, Yanan Ma1, Xiqi Hu1
1Department of Neurosurgery, Haikou Hospital Affiliated with Xiangya Medical College, Central South University, Haikou, China.
Frontiers in neurology
|September 8, 2025
概括
干细胞移植有望通过改善神经功能和减少发作来治疗耐火性. 需要进一步的研究来规范方法并确保长期的安全性和有效性.
科学领域:
- 神经科学是一个神经科学.
- 再生医学是一种再生医学.
- 细胞生物学 细胞生物学
背景情况:
- 影响全球数以百万计的人,其中很大一部分对当前的抗药物 (AED) 具有抗性.
- 耐火性需要超越传统治疗的新疗法策略.
- 干细胞移植成为神经系统疾病的潜在先进疗法.
研究的目的:
- 评估干细胞移植作为耐火性的治疗方法的潜力.
- 在模型中探索干细胞介导的神经改善背后的机制.
- 确定干细胞治疗在管理中的挑战和未来方向.
主要方法:
- 对的干细胞移植的临床前研究和早期临床试验的审查.
- 对包括神经元替代,神经营养因子分泌和免疫调节在内的拟议机制的分析.
- 识别与干细胞移植相关的技术和安全挑战.
主要成果:
- 干细胞移植在模型中显示了神经功能的改善和发作频率的降低.
- 移植的干细胞通过神经保护,神经营养支持 (例如,BDNF) 和抗炎作用来减轻神经元损伤.
- 早期的临床试验表明,接受干细胞治疗的患者的生活质量有所提高.
结论:
- 干细胞移植为治疗耐药提供了一个有前途的途径,解决未满足的临床需求.
- 细胞来源,加工,移植技术的标准化和长期疗效验证至关重要.
- 解决免疫排斥,瘤发生和优化输送方法等挑战对于临床翻译至关重要.
更多相关视频
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
631
06:30Author Spotlight: Advancing Genetic Epilepsy Studies with Multi-Electrode Array-Based Long-Term Electrophysiological Monitoring of Human Brain Assembloids
Published on: September 27, 2024
2.0K
相关概念视频
01:24Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
834
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
834